Balaxi Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Balaxi Pharmaceuticals Ltd reported a 1.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 1.3%.
• Its expenses for the quarter were up by 1.7% QoQ and 11.3% YoY.
• The net profit increased 103.3% QoQ and decreased 92.9% YoY.
• The earnings per share (EPS) of Balaxi Pharmaceuticals Ltd stood at 0.11 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Balaxi Pharmaceuticals Ltd is a pharmaceutical company engaged in the business of manufacturing and distributing pharmaceutical products. As of the data provided, there is no additional information available regarding the company's main products, services, or recent major developments. The company operates within the pharmaceutical industry, which is characterized by the production and marketing of drugs and medical products. It's important to note that without further details, specific insights into Balaxi Pharmaceuticals' product line or strategic initiatives cannot be ascertained.

Revenue

In the fourth quarter of fiscal year 2026 (Q4FY26), Balaxi Pharmaceuticals Ltd reported a total income of ₹73.63 crores. This represents a quarter-over-quarter (QoQ) increase of 1.4% compared to ₹72.64 crores in Q3FY26. However, when compared on a year-over-year (YoY) basis, there is a slight decrease of 1.3% from ₹74.57 crores in Q4FY25. The revenue figures indicate a relatively stable financial performance over the quarters, with a slight dip observed when comparing year-over-year figures. The company's revenue trends are crucial for understanding its market positioning and growth trajectory within the pharmaceutical industry.

Profitability

Balaxi Pharmaceuticals' profitability metrics for Q4FY26 reflect a mixed financial performance. The company recorded a Profit Before Tax (PBT) of ₹1.40 crores, which is a significant decrease both QoQ by 13.0% from ₹1.61 crores in Q3FY26 and YoY by 85.5% from ₹9.66 crores in Q4FY25. The Tax expense was ₹0.79 crores, experiencing a QoQ reduction of 39.2% from ₹1.30 crores in Q3FY26 and a YoY decrease of 23.3% from ₹1.03 crores in Q4FY25. Consequently, the Profit After Tax (PAT) for Q4FY26 is ₹0.61 crores, marking a robust QoQ increase of 103.3% from ₹0.30 crores in Q3FY26, yet a significant YoY decline of 92.9% from ₹8.64 crores in Q4FY25. The Earnings Per Share (EPS) stood at ₹0.11, rising 83.3% QoQ from ₹0.06 but dropping 92.9% YoY from ₹1.56. These fluctuations in profitability metrics are pivotal in assessing the company's financial health and operational efficiency.

Operating Metrics

The total expenses for Balaxi Pharmaceuticals in Q4FY26 amounted to ₹72.23 crores, which signifies a QoQ increase of 1.7% from ₹71.03 crores in Q3FY26 and a notable YoY rise of 11.3% from ₹64.91 crores in Q4FY25. The increasing expenses over the year could potentially impact the company's margins and operational leverage. Unfortunately, specific operating metrics such as P/E ratio, debt-to-equity ratio, and current ratio are not provided within the data, limiting a more detailed analysis of the company's operational efficiency and liquidity. Nonetheless, the observed trends in expenses can provide insights into the company's cost management strategies and their implications on overall financial performance.